Wells Fargo analyst Mohit Bansal maintains Milestone Pharmaceuticals (NASDAQ:MIST) with a Overwei

Milestone Pharmaceuticals Inc. (NASDAQ: MIST) reported first-quarter earnings on Wednesday before th

Milestone® Pharmaceuticals Inc. (NASDAQ:MIST) a biopharmaceutical company focused on the development

EU decision delay for Milestone Pharmaceuticals etripamil, despite strong U.S. launch progress, soli

Milestone Pharmaceuticals (NASDAQ:MIST) reported quarterly losses of $(0.16) per share which met the

Earnings report for Milestone Pharmaceuticals Inc. (MIST) expected on March 19. Analysts predict 16

CARDAMYST is a prescription medication indicated for the conversion of acute symptomatic episodes of

HC Wainwright & Co. analyst Brandon Folkes reiterates Milestone Pharmaceuticals (NASDAQ:MIST)

Aptar Group, Inc. (NYSE:ATR), a global leader in drug and consumer product dosing, dispensing and pr

Wells Fargo analyst Mohit Bansal maintains Milestone Pharmaceuticals (NASDAQ:MIST) with a Overwei

TD Cowen analyst Ritu Baral upgrades Milestone Pharmaceuticals (NASDAQ:MIST) from Hold to Buy and

HC Wainwright & Co. analyst Brandon Folkes maintains Milestone Pharmaceuticals (NASDAQ:MIST)

The FDA approved Milestone Pharmaceuticals' Cardamyst nasal spray for acute episodes of PSVT in

RADX: 471% | Radiopharm Theranostics' Interim Data From The First Twelve Patients In Its U.S. Ph

First FDA approved treatment in 30+ years for more than 2 million Americans with PSVT Novel nasal sp

Milestone Pharmaceuticals (NASDAQ:MIST) reported quarterly losses of $(0.12) per share which beat th

Milestone® Pharmaceuticals Inc. (NASDAQ:MIST), a biopharmaceutical company focused on the developmen

Wells Fargo analyst Mohit Bansal initiates coverage on Milestone Pharmaceuticals (NASDAQ:MIST) wi

Milestone Pharmaceuticals (NASDAQ:MIST) reported quarterly losses of $(0.20) per share which missed

FDA accepts Milestone's response on Cardamyst nasal spray, sets new PDUFA date; company raises $

Milestone® Pharmaceuticals Inc. ("Milestone") (NASDAQ:MIST), a biopharmaceutical company foc

HC Wainwright & Co. analyst Brandon Folkes assumes Milestone Pharmaceuticals (NASDAQ:MIST) wi

Milestone Pharmaceuticals (NASDAQ:MIST) reported quarterly losses of $(0.31) per share which missed

HC Wainwright & Co. analyst Patrick Trucchio maintains Milestone Pharmaceuticals (NASDAQ:MIST

HC Wainwright & Co. analyst Patrick Trucchio reiterates Milestone Pharmaceuticals (NASDAQ:MIS

Milestone Pharmaceuticals' stock drops over 61% after receiving a Complete Response Letter from

The FDA did not raise any concerns regarding etripamil clinical safety or efficacy data and highligh

HC Wainwright & Co. analyst Patrick Trucchio reiterates Milestone Pharmaceuticals (NASDAQ:MIS

HC Wainwright & Co. analyst Patrick Trucchio reiterates Milestone Pharmaceuticals (NASDAQ:MIS

HC Wainwright & Co. analyst Patrick Trucchio reiterates Milestone Pharmaceuticals (NASDAQ:MIS

Milestone Pharmaceuticals (NASDAQ:MIST) reported quarterly losses of $(0.14) per share which beat th

HC Wainwright & Co. analyst Patrick Trucchio reiterates Milestone Pharmaceuticals (NASDAQ:MIS

Shares of Butterfly Network, Inc. (NASDAQ: BFLY) fell sharply during Thursday’s session after the

Shares of Okta, Inc. (NASDAQ: OKTA) shares rose sharply in today’s pre-market trading after the com

Shares of Freshpet, Inc. (NASDAQ: FRPT) gained 15.5% to $106.29 after the company reported better-t

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued c